Radiopharm Theranostics Limited (RADX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Radiopharm Theranostics Limited (RADX) closed at USD 1.12 on 2026-10-14, a change of -78.7 % over the past year, with a market capitalization of USD 15.76M.

Radiopharm Theranostics Limited recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Radiopharm Theranostics Limited key figures

Previous close

USD 1.12 (2026-10-14)

1-year change

-78.7 %

Market cap

USD 15.76M

Enterprise value

USD 9.11M

P/E ratio (trailing)

-0.33

P/E ratio (forward)

-0.47

EPS (trailing)

-3.30

EPS (forward)

-2.32

PEG ratio

n/a

Price to book

0.74

Revenue growth

-36.9 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.67

Employees

14

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Radiopharm Theranostics Limited

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. It is also developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; and RAD402, a PSA-mAb prostate cancer therapeutic. The company was incorporated in 2021 and is based in Carlton, Australia.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Radiopharm Theranostics Limited and compare it with other stocks.